We are excited to introduce SEND Advantage™ Services. Offering study conversions, compliance services and consulting, our new and refreshed services have been designed to help organizations maintain SEND compliance and more.
Join us for a 40-minute webcast to learn more.
Instem CSO, Dr Gordon Baxter, was recently interviewed by Drug Target Review
for an in-depth editorial on Target Safety Assessment.
Join the journey with us by visiting
one of our bi-weekly industry Blogs
Instem Secures Portion of €2.5m Grant as Member of Research Consortium Investigating the Mutagenicity of N-nitrosamines
Newly Added Services to Support Latest Regulatory Guidance and Growing Demand for Alternative Testing Methods
Acquisition of PDS Life Sciences Consolidates Non-Clinical Market; Further Extends Instem’s Leadership in Study Management and Regulatory SEND Submission Support
To help you better evaluate our software or services, we believe an initial, no pressure Web session is the way to go.
© 2022 Instem Group of Companies